Pharmacotherapy for personality disorders

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 10, 2003, Pages 1643-1649

  Newton Howe, Giles ^a,b   Tyrer, Peter ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Paterson Centre   (United Kingdom)

Author keywords

Borderline personality disorder; Drug treatment; Efficacy; Methodology; Randomised trials

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID;

BORDERLINE STATE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; HUMAN; MENTAL HEALTH; MOOD; PERSONALITY; PERSONALITY DISORDER; PSYCHOPHARMACOTHERAPY; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PERSONALITY DISORDERS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0142210247     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.10.1643     Document Type: Review

References (45)

1. AMERICAN PSYCHIATRIC ASSOCIATION: The diagnostic and statistical manual of mental disorders, (3rd edn), American Psychiatric Association, Washington DC (1980).
2. HOCH PH, CATTELL JP, PENNES HH: Effects of mescaline and lysergic acid (d-LSD-25). Am. J. Psych. (1952) 108:579-584.
3. TAHIR RS: Lamotrigine and borderline personality disorder. J. Child Adolesc. Psychopharmacol. (2002) 12:365-366.
4. TYRER P, MITCHARD S, METHUEN C et al.: Treatment-rejecting and treatment-seeking personality disorders: Type R and Type S. J. Personal. Disord. (2003) 17:265-270.
5. WORLD HEALTH ORGANISATION: Mental and Behavioural Disorders: ICD-10, Chapter V; Diagnostic Criteria for Research. World Health Organisation, Geneva (1993).
6. KAPFHAMMER H-P, HIPPIUS H: Pharmacotherapy in personality disorders. J. Personal. Disord. (1998) 12:277-288.
7. WIDIGER TA: Categorical verses dimensional classification: Implications from and for research. J. Personal. Disord. (1992) 6:287-300.
8. LIVESLEY WJ: Commentary on reconceptualizing personality disorder categories using trait dimensions. J. Personal. Disord. (2001) 69:277-286.
9. PERINPANAYAGAM MS, HAIG RA: Use of depot tranquillisers in disturbed adolescent girls. Br. Med. J. (1977) 1:835-836.
10. BRINKLEY JR, BEITMAN BD, FRIEDEL RO: Low dose neuroleptic regimes in the treatment of borderline patients. Arch. Gen. Psych. (1979) 36:319-326.
11. SERBAN G, SIEGAL S: Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am. J. Psychiatry. (1984) 141:1455-1458.
12. SIEVER LJ, DAVIS KL: A psychobiologic perspective on the personality disorders. Am. J. Psychiatry (1991) 148:1647-1658.
13. GOLDBERG S, SCHULZ S, SCHULZ PM et al.: Borderline and schizotypal personality disorder treatment with low dose thiothixene versus placebo. Arch. Gen. Psych. (1986) 43:680-686.
14. SOLOFF PH, GEORGE A, NATHAN RS et al.: Progress in pharmacotherapy of borderline disorders: a double blind study of amitriptyline, haloperidol and placebo. Arch. Gen. Psych. (1986) 43:691-697.
15. COWDRY R, GARDNER DL: Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine trifluoperazine and tranylcypromine. Arch. Gen. Psychiatry (1998) 45(2):111-119.
16. CORNELIUS JR, SOLOFF PH, PEREL JM et al.: Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am. J. Psychiatry (1993) 150:1843-1848.
17. ZANARINI MC, FRANKENBURG FR: Olazapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J. Clin. Psychiatry (2001) 62:849-854.
18. KOENIGSBERG HW, REYNOLDS D, GOODMAN M et al.: Risperidone in the treatment of schizotypal personality disorder. J. Clin. Psychiatry (2003) 64:626:34.
19. BENEDETTI F, SFORZINI L, COLOMBO C et al.: Low dose clozapine in acute and continuation treatment of severe borderline personality disorder. J. Clin. Psychiatry (1998) 59:103-107.
20. FRANKENBURG FR, ZANARINI MC: Clozapine treatment of borderline patients: a preliminary study. Compr. Psychiatry (1993) 34:402-405.
21. ZULLINO DF, HAEFLIGER QP, STIGLER M: Olanzapine improves social dysfunction in cluster B personality disorder. Hum. Psychopharmacol. (2002) 17:247-251.
22. SOLOFF PH: Is there any drug treatment of choice for the borderline patient? Acta Psychiatr. Scand. (1994) 89(Suppl. 379):50-55.
23. HORI A: Pharmacotherapy for personality disorders. Psychiatry Clin. Neurosci. (1998) 52:13-19.
24. COCCARO EF, KAVOUSSI RJ: Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch. Gen. Psychiatry (1997) 54:1081-1088.
25. SALZMAN C, WOLFSON AN, SCHATZBERG A et al.: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disord. J. Clin. Psychopharmacol. (1995) 15:23-29.
26. CORNELIUS JR, SALLOUM IM, EHLER JG et al.: Fluoxetine in depressed alcoholics - a double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (1997) 54:700-705.
27. TYRER P, GUNDERSON J, LYONS M et al.: Extent of comorbidity between mental state and personality disorders. J. Personal. Disord. (1997) 11:242-259.
28. VERKES RJ, VAN DER MAST RC, HENGEVELD MW et al.: Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am. J. Psychiatry (1998) 155:543-547.
29. SOLOFF PH, CORNELIUS JR, GEORGE A et al.: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch. Gen. Psych. (1993) 50:377-385.
30. RIFKIN A, QUITKIN F, CARRILLO C et al.: Lithium carbonate in emotionally unstable character disorder. Arch. Gen. Psych. (1972) 27:519-523.
31. SHEARD MH, MARTIN JL, BRIDGES CI et al.: The effect of lithium on unipolar aggressive behaviour in man. Am. J. Psych. (1976) 133:1409-1413.
32. LINKS PS, STEINER M, BOIAGO I, IRWIN D: Lithium therapy for borderline patients: preliminary findings. J. Personal. Disord. (1990) 4:173-181.
33. TYRER SP, WALSH A, EDWARDS DE et al.: Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry (1984) 8:751-755.
34. GARDNER DL, COWDRY RW: Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. Am. J. Psych. (1986) 143:519-522.
35. DE LA FUENTA JM, LOSTRA F: A trial of carbamazepine in borderline personality disorder. Eur. Neuropsychopharmacol. (1994) 4:479-486.
36. FRANKENBURG FR, ZANARINI MC: Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J. Clin. Psychiatry (2002) 63:442-446.
37. HOLLANDER E, TRACY KA, SWANN AC et al.: Divalproex in the treatment of impulsive aggression: efficacy in Cluster B personality disorders. Neuropsychopharmacology (2003) 28:1186-1197.
38. REICH J, NOYES R, YATES W: Alprazolam treatment of avoidant personality traits in social phobic patients. J. Clin. Psychiatry (1980) 50:91-95.
39. SEIVEWRIGHT H, TYRER P, CASEY P et al.: A three-year follow-up of psychiatric morbidity in urban and rural primary care. Psychol. Med. (1991) 21:495-503.
40. BOHUS MJ, LANDWEHRMEYER GB, STIGLMAYR CE et al.: Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J. Clin. Psychiatry (1999) 60:598-603.
41. NUTT D, JOHNSON FN: Potential applications of venlafaxine. Reviews In Contemporary Pharmacotherapy (1998) 9:321-331.
42. TYRER P, SEIVEWRIGHT N, FERGUSON B et al.: The Nottingham Study of Neurotic Disorder: effect of personality status on response to drug treatment, cognitive therapy and self-help over two years. Br. J. Psychiatry (1993) 162:219-226.
43. EKSELIUS L, VON KNORRING L: Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Int. Clin. Psychopharmacol. (1998) 13:205-211.
44. AMERICAN PSYCHIATRIC ASSOCIATION: Practice guideline for the treatment of patients with borderline personality disorder. Am. J. Psychiatry (2001) 158(Suppl.):1-52.
45. TYRER P: Practice guideline for the treatment of personality disorders: a bridge too far. J. Personal. Disord. (2002) 16:113-118.